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Microbial transformation of lovastatin by B. bassiana 3011. Introduction
Microbial transformation is an efﬁcient and key means for
structural modiﬁcation of organic compounds, especially natural
products with complicated structures1–3. And this approach has
some advantages over organic synthesis such as high stereo- and
regio-selectivity, environmental benignancy, etc4,5. Most impor-
tantly, microbial transformation can carry out some reactions
which chemical approach can not. For example, the introduction
of functional group such as hydroxyl group is usually difﬁcult for
chemical synthesis, but could be readily accomplished by microbial
transformation5–7.
Lovastatin [(1S,2S,20S,6R,8S,8aR,11R,13R)-(1,2,6,7,8,8a-
hexahydro-11,13-dihydroxy-2,6-dimethyl-8-(2-methyl-butyryl)-
oxy-1-naphthalene heptanoic acid-11-lactone), mevinolin and
monacolin K], a fungal metabolite isolated from cultures of
Aspergillus terreus, is a potent competitive inhibitor of the
enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, a rate-limiting enzyme in cholesterol biosynth-
esis8–13. And it is an effective plasma cholesterol-lowering
agent in test animals and humans and has been approved to
be used in clinic. However, lovastatin and its derivatives
exhibited side effects. Their most serious side effects are
increasing in creatinine kinase and myopathy. In patients
treated with lovastatin only, the incidence of skeletal muscle
toxicity is 0.1% to 0.2%. This risk markedly increases when
lovastatin is co-administered with drugs such as cyclosporine14.
Thus, it is of interest to search derivatives with better activity
and lower toxicity via structural modiﬁcation. There have been
some reports on microbial transformation of lovastatin, and
the occurred reactions were involved in hydroxylation at C-3,
C-4, CH3-2 and C-8a positions and isomerization rearrange-
ment at C-8 and C-3(4) double bond11,12. Herein, we report the
microbial transformation of lovastatin by resting cells of a
ﬁlamentous fungus, Beauveria bassiana AS 3.4270, the struc-
tural elucidation of compounds 5, 6 (Fig. 1) and the inhibitory
effects of transformed products on HMG-CoA reductase.Figure 1 A proposed biotransformation pathway of lov2. Results and discussion
Of the 26 used microbial strains (see Experimental section),
B. bassiana AS 3.4270 exhibited the ability to transform
lovastatin (1) into its polar derivatives determined by TLC
and HPLC analyses. Therefore, this strain was selected out for
the preparative scale transformation. Incubation of 1 with the
resting cells of B. bassiana in phosphate buffer solution (PBS,
pH 6.0) afforded ﬁve metabolites 2–6 (Fig. 1). Additionally,
the physical and chemical data of these compounds were
supplemented in this article. Though the compounds 5 and 6
were known, the conﬁgurations of the chiral carbon C-30 were
not determined in the previous report15.2.1. Structural elucidation of 5 and 6
Compound 5 gave a pseudo-molecular ion peak at m/z
453.2808 in HR-ESI-MS (positive ion mode) spectrum, corre-
sponding to the molecular formula of C25H40O7 (six unsatu-
rated degrees). It indicated that 5 contained two more oxygen
atoms compared with 1. The IR spectrum showed the presence
of hydroxy and carbonyl functionalities (3404 and 1724 cm1),
and the latter was further supported by carbon signals at dC
172.9 and 175.2 in the 13C NMR spectrum. The 13C NMR and
DEPT spectra of 5 disclosed 25 carbon signals which were
recognized as 5 methyls (including one methoxy), 5 methy-
lenes, 12 methines (including 4 oxygen-bearing methines), and
3 quaternary carbon atoms including 2 carbonyl carbons. The
NMR spectroscopic data were analogous to those of the
known compound 39 except an additional methoxy signals (dH
3.71 (3H, s), dC 51.8) was observed. Moreover, the upperﬁeld
shift of C-11 (dC 71.0) together with the downﬁeld shift of
C-13 (dC 68.8), C-14 (dC 41.6), and C-15 (dC 172.9) comparing
with those of 3, implied the lactone ring opening and
methylation of the carboxyl. The HMBC correlation from
methoxy proton (dH 3.70, H3-100) to the ester carbon (dC 172.9,astatin (1) to 2–6 by Beauveria bassiana AS 3.4270.
Lirui Qiao et al.302C-15) further conﬁrmed the deduction (Fig. 2). The conﬁg-
uration for C-30 was assigned by comparing the chemical shifts
with the compound 3. As the reported, conﬁguration of C-30
was assigned S when the chemical shifts of H-30 was shifted
downﬁeld to d 4.06, whereas conﬁguration of 30 was assigned
R when the chemical shifts of H-30 was shifted upperﬁeld to d
3.90 (Tables 1 and 2). Thus, the structure of 5 was elucidated
as (1S,2S,20S,30S,6R,8S,8aR,11R,13R)-(1,2,6,7,8,8a-hexahydro-
11,13-dihydroxy-2,6-dimethyl-8-(2-methyl-3-hydroxy-butyryl)oxy-
1-naphthalene heptanoic acid methyl ester.
The molecular of 6 was determined to be C25H40O7 by
HR-ESI-MS (m/z 453.2808 [MþH]þ, calcd. for C25H41O7,
453.2847). It had UV, and NMR spectroscopic featuresOH
O
O
H
HO
O O
OH
5
Figure 2 Key HMBC correlations (H-C) of metabolite 5.
Table 1 1H NMR spectroscopic data for compounds 2–6a,b.
Position 2 3 4
1 1.381.70 1.77 1.74
2 2.222.43,
overlapped
2.40, overlapped 2.37, over
3 5.78 dd (9.9, 6.3) 5.81 5.81
4 5.99 d (9.6) 6.00 d (9.9) 6.00 d (9.3
5 5.50 br s 5.53 br s 5.52 br s
6 2.222.43,
overlapped
2.48 2.44, over
7 1.381.70 1.881.97 1.96
8 5.40 br s 5.41 br s 5.42 br s
8a 2.222.43,
overlapped
2.25 d (12.6) 2.28, over
9 1.381.70 1.54, 1.39 1.56, 1.30
10 1.29, 1.38 1.35, 1.81 1.42
11 3.78 4.63 4.63
12 2.47, 1.38 1.93 1.89, 1.74
13 4.25 4.33 4.32
14 2.49 2.76 dd (17.7, 4.8), 2.62 dd
(17.4, 4.8)
2.71 dd (1
(17.4, 4.8)
20 2.222.42,
overlapped
2.51, overlapped 2.43, over
30 1.371.68 4.06 3.90
40 0.86 1.19 d (6.0) 1.20 d (6.3
20-CH3 1.10 1.14 d (6.9) 1.13 d (6.9
2-CH3 0.89 0.90 d (6.9) 0.89 d (6.3
6-CH3 1.08 1.08 d (7.2) 1.07 d (6.3
10 0 3.71 s
aData were measured in CDCl3. Coupling constants (J in Hz) are g
HSQC and HMBC experiments.
bRecorded at 300 MHz for compounds.similar to those of 5, except that different values of the
chemical shift corresponding to H-30 (dH 3.90, m) and the
C-30 (dC 69.6) compared with those of 5. This implied that
conﬁguration for 30-OH in 6 was opposite to that in 59. It was
further supported by the chemical shift of C-30 identical to
that in 4. Thus, 6 was identiﬁed as (1S,2S,20S,30R,6R,8S,8aR,
11R,13R)-(1,2,6,7,8,8a-hexahydro-11,13-dihydroxy-2,6-
dimethyl-8-(2-methyl-3-hydroxy-butyryl)oxy-1-naphthalene
heptanoic acid methyl ester.2.2. HMG-CoA reductase inhibitory activity bioassay
Metabolites 2–6 together with substrate 1 were examined for
their inhibitory effects on the enzyme HMG-CoA reductase
in vitro by using atorvastatin as positive control16. Metabolite
4 showed comparable inhibitory activity on HMG-CoA
reductase to 1 (Table 3). Metabolites 2, 3, 5 and 6 exhibited
weaker activities than lovastatin. From the structural features
of the lovastatin, it was found that the hydroxylation at C-30
(3 and 4) decreased the activity, especially for S conﬁguration
of C-30 (3). Though the hydroxy acid form was the active form
of lovastatin9,10, metabolites 2, 5 and 6 with methyl ester of
lactone opened ring were signiﬁcantly less effective than
lovastatin, which obviously suggested that methyl ester of
lactone opened ring substantially led to the decrease of the
inhibitory effect on the HMG-CoA reductase.5 6
1.75 1.74
lapped 2.36,
overlapped
2.37, overlapped
5.81 5.81
) 6.00 d (9.6) 6.00 d (9.3)
5.52 br s 5.52 br s
lapped 2.42 2.44, overlapped
2.06, 1.9 1.96
5.40 br s 5.42 br s
lapped 2.28 br d
(12.6)
2.28, overlapped
1.54, 1.32 1.56, 1.30
1.66 1.42
3.90 3.90
1.60 1.89, 1.74
4.23 4.32 (1H)
7.7, 4.5); 2.61 dd 2.50 2.71 dd (17.7, 4.5), 2.61 dd
(17.4, 4.8)
lapped 2.51,
overlapped
2.43, overlapped
4.12 3.90
) 1.19 d (6.3) 1.20 d (6.3)
) 1.13 d (6.9) 1.13 d (6.9)
) 0.88 d (6.9) 0.89 d (6.3)
) 1.07 d 1.07 d (6.3)
3.71 s 3.71 s
iven in parentheses. The assignments were based on the gCOSY,
Table 2 13C NMR data for compounds 2–6a,b.
Position 2 3 4 5 6
1 36.2 36.7 36.6 36.1 36.0
2 30.5 30.6 30.6 30.5 30.5
3 133.3 133.2 133.2 133.4 133.4
4 128.2 128.2 128.3 128.2 128.2
4a 131.7 131.6 131.6 131.8 131.9
5 129.5 129.6 129.5 129.5 129.4
6 27.5 27.4 27.4 27.5 27.5
7 32.8 32.7 32.6 32.5 32.8
8 67.9 68.5 68.6 68.5 68.4
8a 37.5 37.3 37.1 37.4 37.3
9 24.1 23.8 23.5 22.7 22.4
10 34.7 32.6 32.2 34.1 33.9
11 72.3 76.0 76.2 71.0 71.0
12 41.4 35.8 35.5 42.0 42.0
13 69.0 62.4 62.4 68.8 68.8
14 42.3 38.5 38.5 41.6 41.5
15 172.9 170.7 170.6 172.9 172.9
10 176.8 175.6 176.1 175.2 176.2
20 41.4 45.7 47.7 45.9 48.1
30 26.8 68.1 69.4 68.0 69.6
40 11.7 20.0 20.6 20.0 20.9
20-CH3 16.2 10.2 13.9 9.7 14.1
2-CH3 13.9 13.8 13.8 13.8 13.9
6-CH3 22.8 22.8 23.0 22.7 22.9
10 0 51.8 51.8 51.8
aData were measured in CDCl3. Assignments based on the
gCOSY, HSQC and HMBC experiments.
bRecorded at 100 MHz for compounds.
Table 3 Inhibitory effects of compounds 1–6 on the
HMG-CoA reductase in vitro.
Compound Concentration
(mM)
Inhibition
(%)b
IC50
(mM)
Atorvastatina 10 93.0 0.081
Lovastatin 10 83.5 0.52
2 10 32.3 410
3 10 67.4 7.2
4 10 81.4 2.2
5 10 46.2 410
6 10 52.3 410
aAtorvastatin was used as positive control.
bInhibition (%)¼ [(ODsampleODcontrol)/(ODblankODcontrol)]
 100%.
Microbial transformation of lovastatin by B. bassiana 3032.3. The time courses of biotransformation of 1 to 2, 3, 4, 5
and 6
The time courses of 1 to the metabolites 2, 3, 4, 5 and 6 were
investigated. The results (Fig. 3) displayed that: (1) the substrate
(lovastatin) was stable after 12, 24 and 60 h of incubation in
blank 0.02 M phosphate buffer (pH 6.0), respectively; (2) after
12 h of incubation, the yield of the major metabolite 2, reached
the maximal amount, about 14.6 mg/L, after which it decreased;
(3) the yields of the metabolites 3 and 4, increased slowly, andtheir yields were just 5.7 and 2.4 mg/L, respectively; (4) after 72 h
of incubation, the metabolites 5 and 6 started increasing, and the
yields reached 3.5 and 2.2 mg/L, respectively. The results of the
decreasing yield of 2 and increase of the yield of 5 and 6 after
84 h suggested that 5 and 6 might be biosynthesized from 2 via
the different stereo-selectivity of hydroxyl group at C-30 in
aliphatic region. And 3 and 4 might be yielded from 1 through
a non-stereo-speciﬁc hydroxylation at C-30. Their possible
biosynthetic origins are proposed as shown (Fig. 1).
In the transformation of lovastatin by B. bassiana, ﬁve
metabolites 2–6 were obtained, and three reaction types including
hydroxylation of C-3, lactone hydrolysis and methylation of
heptanoic acid were observed. To the best of our knowledge, it is
the ﬁrst report on the hydroxylation at C-30 and methylation of
hepanoic acid form of lovastatin by microbial transformation.
Though the inhibitory effects on HMG-CoA reductase of all the
metabolites were weaker than that of lovastatin, the results still
contribute the summary of structure–activity relationships of this
type compounds as mentioned above.3. Experimental
3.1. General experimental procedures
Optical rotations were measured on a Perkin-Elmer Model-
343 digital polarimeter. The UV spectral data were recorded
on a JASCO J-815 spectropolarimeter. IR spectra were
recorded on a Nicolet 5700 FT-IR microscope spectrometer
(FT-IR Microscope Transmission). 1D and 2D NMR spectro-
scopic data were obtained at 300 MHz or 400 MHz for
1H NMR and 100 MHz for 13C NMR on Mercury-300 and
Mercury-plus-400 spectrometers, respectively. Chemical shifts
(d) are given in ppm, coupling constants (J) are given in hertz
(Hz). ESI-MS data and HR-ESI-MS data were measured
using an Agilent Technologies 6520 Accurate Mass Q-TOF
LC/MS spectrometer. Column chromatography was performed
with silica gel (200–300 mesh, Qingdao Marine Chemical Inc.,
Qingdao, China). Semi-preparative normal phase HPLC was
performed on a Shimadzu LC-6AD instrument with an Apollo
silica gel column (5 mm, 250 mm 10 mm, i.d.) and a Shimadzu
RID-10A detector. Semi-preparative reversed phase HPLC was
carried out on the same instrument with a YMC-Pack ODS-A
(5 mm, 250 mm 10 mm, i.d.), and analytical TLC was carried
out on pre-coated silica gel GF254 plates (Qingdao Marine
Chemical Inc., Qingdao, China). Spots were visualized under UV
light and by spraying with 10% H2SO4 in EtOH followed by
heating at 120 1C. Unless otherwise noted, all chemicals were
obtained from commercially available sources and were used
without further puriﬁcation.
3.2. Substrate, organisms and cultivation conditions
Lovastatin (498% by HPLC) was purchased from Nanjing
Zelang Medical Technology Co., Ltd., and characterized by
comparison of the NMR data with the references13, and
dissolved in N,N-dimethylformamide (DMF) at the concen-
tration of 50 mg/mL before use. The strains (Absidia coerulea
Bainier AS 3.3389, A. coerulea Bainier AS 3.3538, A. coerulea
Bainier Z-1, A. coerulea Bainier Z-2, Alternaria alternate AS
3.577, Aspergillus niger Van Tieghem AS 3.739, A. niger Van
Tieghem AS 3.795, A. niger Van Tieghem Z-3, A. terreus
Figure 3 Time courses of the biotransformation of 1 to 2, 3, 4, 5 and 6 by resting cells of ﬁlamentous fungus, Beauveria bassiana
CGMCC 3.4270.
Lirui Qiao et al.304IMM-A8-4, Beauveria bassiana AS 3.4270, Cunninghamella
echinulata AS 3.3400, C. elegans AS 3.3402, Curvularia lunata
AS 3.3589, Geotrichum sp. AS 3.1031, Mucor javanicus AS
3.193, Nocardia purpurus AS 4.1182, Penicillium spinulosum
AS 3.149, Phyllosticta pirina AS 3.2886, Rhizopus stolonifer
AS 3.3463, Rhodococcus AS 4.1147, Streptomyces hygroscopi-
cus AS 4.1114, Streptomyces sp IAA-82, Streptomyces sp.
IAA-601, Streptomyces sp. IAA-602, Streptomyces sp. IAA-
603, Trichoclerma sp. AS 3.3068) were purchased from China
General Microbiological Culture Collection Center coded AS,
gifted from Professor Ligang Zhou of Chinese Agriculture
University coded Z, gifted from China Center for Antibiotics
Culture Collection (Beijing) coded IAA, and deposited in Institute
of Materia Medica (Chinese Academy of Medical Sciences) coded
IMM, respectively. The fungal strains were kept on solid potato
dextrose agar (PDA) medium containing potato (200 g/L), dex-
trose (20 g/L), KH2PO4 (3 g/L), anhydrous MgSO4 (0.75 g/L) and
agar (2%) at 4 1C. The actinomycetic strains were maintained on
solid CM0038 medium containing yeast extract (5 g/L), soy
peptone (5 g/L), dextrose (20 g/L), NaCl (5 g/L), K2HPO4 H2O
(6.55 g/L) and agar (2%) at 4 1C. The medium was used after
autoclaving at 121 1C for 25 min. The seed cultures were prepared
in a 250 mL ﬂasks with 70 mL liquid medium (PDA and CM0038
media without agar) by incubating 2 days. A volume of 5 mL of
the seed cultures was added to each ﬂask and shaken at 110 r/min
at 2572 1C in the dark for the use of biotransformation.3.3. Screening biotransformation
For screening test, the fungal and actinomycetic strains were
incubated as described above. 2-day-old cell cultures were
employed for biotransformation. A volume of 140 mL of
substrate solution with ﬁnal concentration of 100 mg/L was
fed to one ﬂask. The incubation was allowed to proceed for 4
days, after which the cultures were ﬁltered and extracted with
ethyl acetate (3 1 L). The extract was dried with anhydrous
Na2SO4 and concentrated under vacuum at 45 1C to give
residue, and analyzed by TLC and HPLC.3.4. Preparative biotransformation, extraction, isolation and
identiﬁcation of metabolites
The 2-day-old seed cultures of B. bassiana were added to the 1 L
Erlenemeyer ﬂasks containing 300 mL of liquid mediumaccording to the standard two-stage fermentation protocol. After
2 days of incubation, 20 L of cultures were ﬁltrated under
vacuum to obtain the mycelia. Then the mycelia were re-
suspended in 67 1L Erlenemeyer ﬂasks containing 300 mL of
0.02 M phosphate buffer (0.012 mol Na2HPO4, 0.088 mol
NaH2PO4 in 1 L of distilled water, pH 6.0). Lovastatin (2 g in
40 mL DMF) was evenly distributed into the ﬂasks, and
incubated at 26 1C in a rotary shaker at 110 r/min. After 48 h
of incubation, the mycelia were ﬁltrated. The resulting mycelia
were dried at 60 1C, and then extracted with the mixture of
methanol and acetone (1/1, v/v) three times. The residue (9.2 g)
contained the substrate and one main metabolite through TLC
analysis and was subjected onto a silica gel chromatography
column by eluting with petroleum-ether (60–90 1C)/acetone to
provide ten fractions (Fr.1–Fr.10). Residual substrate (1, 903 mg,
45%) was recycled from Fr.5. Fr.6 (1.35 g) was separated by
Sephadex LH-20 column chromatography eluting with chloro-
form/methanol (40/60, v/v) and further puriﬁed by semi-pre-
parative normal phase HPLC (n-hexane/ethyl acetate, 75/25, v/v)
to yield compound 2 (273 mg, 12.7 %). The ﬁltrate was extracted
with ethyl acetate (3 10 L), dried over anhydrous Na2SO4 and
evaporated under reduced pressure to afford 1.8 g of crude
extract. The crude extract was subjected to column chromato-
graphy with Amberlite XAD-16 macro-porous resin (120 g),
eluting with H2O, 50 % ethanol, 75 % ethanol and ethanol,
successively. The residue of 75 % ethanol fraction (300 mg) was
separated by silica gel column chromatography (n-hexane/ethyl
acetate, 25/75, v/v) to yield 3 fractions A–C. Fraction C (86 mg)
was applied to semi-preparative reverse phase HPLC (75 %
MeOH in H2O, v/v, ﬂow rate 4 mL/min) to afford compound 3
(35 mg, 1.7 %, tR 12.4 min) and compound 4 (20 mg, 0.9%, tR
14.0 min). Fraction B (75 mg) was puriﬁed by semi-preparative
reverse phase HPLC (75 % MeOH in H2O, v/v, ﬂow rate 4 mL/
min) to give 5 (18 mg, 0.8%, tR 18.3 min). Fraction A (28 mg)
was submitted to a semi-preparative normal phase HPLC (n-
hexane/ethyl acetate, 66/34, v/v, ﬂow rate 4 mL/min) to yield
compound 6 (6 mg, 0.3%, tR 14.0 min).
3.5. (1S,2S,20S,6R,8S,8aR,11R,13R)-(1,2,6,7,8,8A-Hexahydro-
11,13-dihydroxy-2,6-dimethyl-8-(2-methylbutyryl)oxy-1-
naphthalene heptanoic acid methyl ester (2)17
Yellow oil, [a]20D þ 16.0 (c 1.1, MeOH); UV (MeOH) lmax
nm (log e), 203 (3.81), 229 (3.59), 237 (3.61), 245 (3.50);
IR nmax 3420, 2963, 2934, 1725, 1458, 1440, 1381, 1262,
Microbial transformation of lovastatin by B. bassiana 3051192, 1156, 1079, 1013 cm1; 1H NMR data see Table 1; 13C
NMR data see Table 2; ESI-MS m/z 437 [MþH]þ.
3.5.1. (30S)-30-Hydroxy-lovastatin (3)9
White crystalline solid, mp: 104–105 1C, [a]20D þ 41.6 (c 0.7,
MeOH); UV (MeOH) lmax nm (log e), 204 (4.01), 229 (4.05),
237 (4.08), 246 (3.93); IR nmax 3423, 2967, 2931, 1716, 1454,
1379, 1260, 1230, 1193, 1075, 1053, 1003 cm1; 1H NMR data
see Table 1; 13C NMR data see Table 2; ESI-MS m/z 421
[MþH]þ, 443 [MþNa]þ.
3.5.2. (30R)-30-Hydroxy-lovastatin (4)9
White crystalline solid, mp: 131–132 1C, [a]20D þ146.8 (c 0.3,
MeOH); UV (MeOH) lmax nm (log e), 230 (4.22), 237 (4.27),
246 (4.09); IR nmax 3500, 3351, 2965, 2927, 2873, 1727, 1693,
1450, 1392, 1253, 1184, 1118, 1056 cm1; 1H NMR data see
Table 1; 13C NMR data see Table 2; ESI-MS m/z 421
[MþH]þ, 863 [2MþNa]þ.
3.5.3. (1S,2S,20S,30S,6R,8S,8aR,11R,13R)-(1,2,6,7,8,8a-
Hexahydro-11,13-dihydroxy-2,6-dimethyl-8-(2-methyl-3-hydroxy-
butyryl)oxy-1-naphthalene heptanoic acid methyl ester (5)
Yellow oil, [a]20D þ 62.9 (c 1.3, MeOH); UV (MeOH) lmax nm
(log e), 203 (3.83), 229 (3.59), 236 (3.56), 247 (3.41); IR nmax
3404, 2935, 1724, 1440, 1379, 1262, 1192, 1092, 1032,
1004 cm1; 1H NMR data see Table 1; 13C NMR data see
Table 2; ESI-MS m/z 453 [MþH]þ, 475 [MþNa]þ; HR-ESI-
MS m/z 453.2808 [MþH]þ (calcd. for C25H41O7, 453.2847).
3.5.4. (1S,2S,20S,30R,6R,8S,8aR,11R,13R)-(1,2,6,7,8,8a-
Hexahydro-11,13-dihydroxy-2,6-dimethyl-8-(2-methyl-3-
hydroxy-butyryl)oxy-1-naphthalene heptanoic acid methyl
ester (6)
Yellow oil, [a]20D þ50.2 (c 0.5, MeOH); UV (MeOH) lmax nm
(log e), 203 (3.74), 229 (3.50), 237 (3.43), 246 (3.32); IR nmax
3386, 2935, 1724, 1440, 1381, 1263, 1190, 1109, 1045,
1004 cm1; 1H NMR data see Table 1; 13C NMR data see
Table 2; ESI-MS m/z 453 [MþH]þ, 475 [MþNa]þ; HR-ESI-
MS m/z 453.2808 [MþH]þ (calcd. for C25H41O7, 453.2847).
3.6. HMG-CoA reductase inhibitory activity bioassay
The assay was performed in a UV compatible 96-well plate,
and 6 mg of HMGR enzyme was incubated at 37 1C with
20 mM NADPH, 10 mM HMG-CoA and different concen-
trations of test compounds. The enzymatic reaction was
allowed to proceed for 60 min. HMG-CoA reductase activity
was determined by measuring the decrease of NADPH at
340 nm using an ELISA reader. Inhibition of HMG-CoA
reductase activity was expressed as the percentage decrease in
the OD when HMG-CoA reductase was incubated with the
test compounds16.
3.7. Time courses of the biotransformation of 1 to 2–6
2-day-old cell cultures were employed for resting cell bio-
transformation. 7 mg/ﬂask (100 mg/L, in triplicates) of 1 was
fed to the culture separately. The broth was collected every
12 h and performed as described in section 3.4. The organic
extract was evaporated to dryness, and the residue was
dissolved in 2 mL of methanol. Samples were ﬁltered through0.45 mm (pore size) membranes just prior to HPLC analysis.
An aliquot of 10 mL was used for each injection.
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